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PolymorphismInterleukin-10 (IL-10) is a cytokine that plays an important role in the regulation of the immune system.
Gene polymorphisms of IL-10 have been associated with the different expression levels of this cytokine.
In hepatitis C virus infection, IL-10 appears to interfere with the progression of disease, viral persistence
and the response to therapy. This study investigated genetic variability in the IL-10 gene promoter
between patients infected with hepatitis C virus (HCV) and healthy individuals, associating the frequency
of polymorphisms with different aspects of viral infection. This is a case-control study with 260 patients
who were infected with HCV and 260 healthy individuals. Genotyping of the polymorphisms was per-
formed using the technique of ampliﬁcation refractory mutation system PCR (ARMS-PCR) for regions
of the IL-10 gene promoter (-1082 G/A, -819 C/T, -592 C/A). The frequencies of alleles and genotypes
related to polymorphisms in the IL-10 gene promoter showed a higher frequency of the G allele and geno-
type GG in the -1082 region between the infected group and the control group (p = 0.005 and p = 0.001,
respectively), whereas the AA genotype was signiﬁcantly more frequent in the control group. The fre-
quencies of the haplotypes GTA and GCC were higher in the group of infected individuals, whereas the
haplotype ATA was more frequent in the healthy group (p < 0.006). It was also observed that the geno-
types GG and AG in the region -1082 were signiﬁcantly more frequent among patients infected with
HCV who were in advanced stages of ﬁbrosis and cirrhosis (p = 0.042). No association was observed
between polymorphisms of IL-10 and sustained virologic response (SVR).
 2015 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Approximately 2–3% of the world’s population is chronically
infected with HCV, which is considered a serious public health
and economic problem [1,2]. The prevalence of HCV in Brazil
ranges from 1.5% to 10% of the population, according to data from
the World Health Organization [3].
HCV induces chronic liver disease, which is characterized by a
persistent hepatic parenchyma inﬂammatory process that may
progress to cirrhosis and hepatocarcinoma [4]. Viral clearance
occurs in a minority of patients with viral hepatitis C, whereas
chronic infection is established in 60–80% of all cases, 20–40% ofwhich may evolve to cirrhosis and hepatocarcinoma [5,6].
Genetic differences among the infected hosts can determine the
progression of the infection, causing different individuals to
respond in different ways to the viral infection [7,8].
Cytokines have become the focus of many scientiﬁc studies, as
there is evidence of the contribution of genetic factors to the
imbalance of the inﬂammatory proﬁle of the patient, which
directly affects the clinical outcome and the severity of hepatitis
C and other infectious diseases [9–12]. Experiments have shown
that pro- and anti-inﬂammatory cytokines can modulate the bene-
ﬁts of antiviral therapy, affecting the evolution of liver disease and
viral clearance after the acute phase and causing rapid progression
to decompensated liver disease [6].
IL-10 is produced by Th2 lymphocytes, B lymphocytes, hep-
atocytes, Kupffer cells, epithelial cells and keratinocytes, among
others. This cytokine seems to play an important role in the
immune response against HCV, as it interferes with the balance
of Th1/Th2, negatively regulating the response of Th1 lymphocytes
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interferon gamma [13]. The IL-10 gene contains ﬁve exons that are
separated by four introns and occupies approximately 5.1 kb on
chromosome 1, between 1q31 and 1q32 [14]. Three biallelic
single-nucleotide polymorphisms (SNPs) were described in the
promoter region -1082 (G/A), -819 (C/T) and -592 (C/A). There is
linkage disequilibrium between the SNPs -819 and -592 because
the C allele of -819 is always present when there is a C allele
in -592, whereas the T allele is always present in -819 when the
A allele is in -592 [15,16].
Recent studies indicate that genetic variability in the promoter
region of the IL-10 gene is related to different levels of expression
of this cytokine [9,17]. These levels of expression seem to be
involved in the immune response of patients infected by HCV, in
progression of liver disease and in the response of patients to
antiviral therapy [17,18]. The alleles -1082/G, -819/C and -592/C
(haplotype GCC) have been linked to high production of IL-10
[19], while the haplotype ACC and ATA are associated with lower
levels of expression. Such polymorphisms are directly involved in
the control of the expression levels of IL-10, which plays an impor-
tant role in the depuration of HCV [20].
In view of the contradictory results already published, this
study investigated genetic variability in the IL-10 gene promoter
among patients infected with HCV and healthy individuals, asso-
ciating the frequency of polymorphisms with different aspects of
HCV infection.2. Material and methods
2.1. Patients
This study was conducted between October 2012 and May
2013. Among the patients involved, 260 were chronic carriers of
HCV genotypes 1, 2 and 3 who were receiving antiviral drugs for
HCV at the Center for Application and Monitoring of Injectable
Drugs (CAMMI) in Pelotas and Rio Grande, RS, Brazil. The healthy
group was composed of 260 healthy volunteers at the University
Hospital. These volunteers showed normal liver enzymes, negative
serology for HCV, HBV and HIV and no history of viral hepatitis or
endocrine disorders. This study was approved by the Ethics
Committee at the Federal University of Rio Grande (Approval
No.: 182.257). All patients signed an informed consent form and
responded to a questionnaire for sociodemographic and behavioral
data. Biochemical variables were obtained by reviewing the
patients’ medical records.
2.2. Treatment
All chronic HCV patients received treatment with subcutaneous
injection of conventional interferon (IFN) or pegylated interferon
(PEG-IFN) and oral doses of ribavirin (RBV), adjusted according to
their body weight. Among treated patients, 25 received triple ther-
apy with Ribavirin, PEG-IFN and a protease inhibitor (Boceprevir).
The patients were divided into two groups, according to their vir-
ologic response: SVR, with undetectable HCV-RNA 24 weeks after
the end of treatment; and nonresponder patients (NR), with
detectable HCV-RNA after the same time period.
2.3. Blood samples and laboratory techniques
Venous blood samples (10 mL) were collected from the patients
in tubes containing ethylenediaminetetraacetic acid (EDTA). The
DNA was extracted with a PureLink DNA Genomic Mini Kit
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
instructions. The extracted samples were stored at 20 C forfurther molecular assays. The ampliﬁcation refractory mutation
system PCR (ARMS-PCR) technique was used for SNP genotyping,
as described by Perrey [21]. According to Afzal [22], two reactions
containing an antisense generic primer and a sense allele-speciﬁc
primer were performed for each polymorphism. The primers used
in this study were antisense generic primer 50-CAGTGCCAACTGA
GAATTTGG-30 and sense allele-speciﬁc primer 1 (G) 50-CTACT
AAGGCTTCTTTGGGAG-30 and 2 (A) 50-ACTACTAAGGCTTCTTTGG
GAA-30 for the SNP -1082 (G/A); antisense generic primer 50-AGG
ATGTGTTCCAGGCTCCT-30 and sense allele-speciﬁc primer 1 (C)
50-CCCTTGTACAGGTGATGTAAC-30 and 2 (T) 50-ACCCTTGTACAG
GTGATGTAAT-30 for the SNP -819/-592. All PCR reactions had a
ﬁnal volume of 25 lL, containing 2 lL of DNA, 1X reaction buffer,
dNTPs (1.5 mM), MgCl2 (25 mM), 10 pmol of each primer and 0.4
units of Taq polymerase (Life Technologies, Carlsbad, USA). The
cycling conditions were as follows: 3 min at 95 C, followed by
35 cycles of 95 C for 45 s, 58 C for 40 s and 72 C for 1 min, and
a ﬁnal extension of 7 min at 72 C. The sizes of the fragments were
258 bp and 233 bp for the -1082 and -819/-592 regions, respec-
tively. Human growth hormone was used as an internal control
to conﬁrm the success of the reaction, with primers 1 (50-GCC
TTCCCAACCATTCCCTTA-30) and 2 (50-TCACGGATTTCTGTTGTGT
TTC-30) generating a 429 bp product. The PCR products were
stained in a 2% agarose gel with Blue Green Loading Dye I (LGC
Biotechnology, São Paulo, Brazil).2.4. Statistical analysis
Statistical analyses were performed using the program STATA
8.0, with Fisher and chi-squared tests. Values were considered sig-
niﬁcant when p < 0.05.3. Results
The sociodemographic variables of the individuals involved in
this study are described in Table 1. The average age of patients
infected with HCV was 54.1 ± 11.5 years, signiﬁcantly higher than
48.9 ± 15.1 years in the healthy group (p = 0.0001). The skin color
also showed statistically signiﬁcant differences between patients
with HCV and healthy patients (p = 0.047). As expected, the aver-
age alanine aminotransferase (ALT) and aspartate aminotrans-
ferase (AST) were signiﬁcantly higher in patients with HCV
(p < 0.001).
Analysis of the alleles and genotypes related to polymorphisms
in the IL-10 gene promoter between the study groups showed an
increased frequency of both the G allele in the -1082 region of
the infected group and the A allele in the healthy group (p = 0.01
in both cases). The genotype GG in the same region was signiﬁ-
cantly more frequent in the infected patients (p = 0.01).
Conversely, the AA genotype was signiﬁcantly associated with
the control group (p = 0.01) (Table 2). There were no signiﬁcant dif-
ferences between alleles or genotypes in the polymorphisms of the
-819/-592 region, which shows linkage disequilibrium. In relation
to haplotypes, as shown in Table 3, GTA and GCC were more fre-
quent in the infected patients, although there was no signiﬁcant
association. However, the ATA haplotype was signiﬁcantly more
frequent in the healthy group (p < 0.01). The genotypes GG
and AG were signiﬁcantly more frequent in the -1082 region in
infected individuals with advanced stages of ﬁbrosis and cirrhosis.
No statistically signiﬁcant association was observed for the
region -819/-592 between different haplotypes. As noted, the
genotype of HCV and the stages of hepatic ﬁbrosis were sta-
tistically related because genotype 3 of HCV was signiﬁcantly
associated with advanced ﬁbrosis and cirrhosis (p < 0.033).
Table 1
Sociodemographic and clinical variables in patients with chronic hepatitis C and in healthy patients (n = 520).
Chronic hepatitis C (n = 260) Control group (n = 260) p Valuea
N % N %
Sex 0.313
Female 112 43.1 123 47.3
Male 148 56.9 137 52.7
Skin color 0.047
White 215 83.0 196 75.7
Non-white 45 16.9 63 24.3
Mean (sd) Mean (sd)
Age 54.1 (11.5) 48.9 (15.1) <0.001b
AST 48.2 (35.3) 21.2 (8.1) <0.001b
ALT 51.2 (45.2) 19.7 (7.6) <0.001b
a Chi-squared test.
b Student’s T test.
Table 2
Frequency of alleles and genotypes in the regions -1082 and -819/-592 of the IL-10 gene promoter in patients with chronic hepatitis C and in healthy patients (n = 520).
Locus Chronic hepatitis C (n = 260) Healthy group (n = 260) p Valuea
N % N %
Genotypes
-1082 <0.001
AA 23 8.8 40 15.4 0.031
GA 191 73.5 202 77.7 0.307
GG 46 17.7 18 6.9 <0.01
-819/-592 0.161
TT/AA 58 22.3 48 18.5 0.327
CT/CA 171 65.8 190 73.1 0.087
CC/CC 31 11.9 22 8.4 0.113
Alleles
-1082 0.005
A 237 45.6 282 54.2 <0.01
G 283 54.4 238 45.8 <0.01
-819/-592 0.950
T/A 287 55.2 286 55 0.999
C/C 233 44.8 234 45 0.999
a Chi-squared test.
Table 3
Haplotypes in the regions -1082 and -819/-592 of the IL-10 gene promoter in patients with chronic hepatitis C and in healthy patients (n = 520).
IL-10 haplotype Chronic hepatitis C (n = 260) Healthy group (n = 260) p Valuea
N % N % 0.006
ATA 16 6.1 38 14.6 p < 0.01
ACC 7 2.7 2 0.8 p = 0.176
GTA 213 82.0 200 76.9 p = 0.193
GCC 24 9.2 20 7.7 p = 0.637
a Chi-squared test.
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signiﬁcantly associated with the absence of sustained virologic
response (p = 0.001). Among the 261 patients infected with HCV
who were attending reference centers to receive antiviral treat-
ment, 232 (88.9%) were undergoing treatment with PEG-IFN and
RBV, 25 (9.6%) were receiving triple therapy (PEG-IFN, RBV and
Boceprevir) and 3 (1.1%) were receiving conventional IFN. One
patient (0.4%) did not adhere to the treatment or return to the cen-
ter. Thus, of the 260 treated patients, 160 (61.5%) presented RVS,
147 (91.9%) of whom were treated with PEG-IFN and RBV, and
13 (8.1%) received triple therapy. Only one of the three patients
treated with IFN presented SVR. These data showed no association
between IL-10 gene polymorphisms and SVR but did showdifferences in the genotypic proﬁle of IL-10 between infected and
healthy patients.
According to Table 4, it is noted that patients with genotype 1
and 3 presents the most advanced degree of ﬁbrosis as compared
genotype 2 (p < 0.033). Degree of Inﬂammation was no signiﬁcant
association between HCV genotypes.4. Discussion
This study was performed in reference centers for the treatment
of HCV in southern Brazil, allowing us to map the demographic,
clinical and immunogenetic proﬁles of patients infected by HCV.
Table 4
HCV genotypes associated with the degree of hepatic ﬁbrosis and inﬂammation
(according to the METAVIR scale) (N = 260).
G1 G2 G3 p-Valuea
N % N % N %
Fibrosis 0.033
F0 8 6.6 4 25.0 5 4.1
F1 28 23.1 4 25.0 38 30.9
F2 51 42.2 5 31.3 42 34.1
F3 27 22.3 2 12.5 22 17.9
F4 7 5.8 1 6.2 16 13.0
Inﬂammation 0.238
A0 6 5.0 2 12.5 4 3.3
A1 41 33.9 8 50.0 52 42.3
A2 68 56.2 6 37.5 65 52.8
A3 6 4.9 0 0.0 2 1.6
a Chi-square test.
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as gender, age and ethnicity, contribute to the progression of hep-
atitis C virus infection and to the response to antiviral therapy
among infected individuals [19]. In recent years, the immuno-
genetics of the hosts have been studied in an attempt to under-
stand predictive factors for a cure or disease progression at the
onset of an HCV infection. The relationship between polymor-
phisms in the promoter of IL-10 and the outcome of infection
and response to treatment against HCV has been discussed because
the results obtained thus far are conﬂicting [6,17,18].
IL-10 is an anti-inﬂammatory cytokine that plays an important
role in the regulation of the immune response. The expression
levels of this cytokine are associated with viral persistence due
to the direct action of IL-10 on the mechanisms of innate and adap-
tive immunity [23,24]. Variations in these levels have been directly
related to the inﬂuence of IL-10 on the organization of the immune
response and are associated with the presence of polymorphisms
in the IL-10 gene [25–33]. Most published studies demonstrate a
relationship between chronic HCV infection and high levels of IL-
10 production, conﬁrming that some polymorphisms in the IL-10
gene promoter are crucial to determine the course of infection
and eliminate the viral agent [34–36].
The analysis of polymorphisms in the IL-10 gene promoter
regions -1082 A/G and -819 C/T (-592 C/A) in patients in this study
demonstrated that the genotype -1082 GG is more frequent in
individuals infected with HCV than in healthy individuals. The
genotype -1082 GG is responsible for high levels of IL-10 produc-
tion, which then undermine the antiviral cellular immune response
[20]. These results are in agreement with previously published
data [37,38] and corroborate the study by Afzal et al. [22], who
reported a signiﬁcant frequency of the genotype -1082 GG in 17%
of patients with chronic HCV infection and 3% of patients from
the healthy group. Conversely, Knapp et al. [39] reported an
association of the genotype -1082 AG with viral infection. Other
authors have not observed a signiﬁcant difference in the polymor-
phisms of the -1082 and -819/-592 regions of the IL-10 gene pro-
moter between infected and healthy patients [6,40–44]. The
genotype -1082 AA showed a higher frequency in the healthy
group, in contrast to other studies that associated this genotype
with patients infected with HCV [37,38,44].
Signiﬁcant differences were not observed in the analysis of
polymorphisms in the regions -819/-592 between infected and
healthy patients in our study, which is in accordance with the data
published by other authors [7,22,37,40,42,45–47]. In contrast, a
few studies have shown the association of this polymorphism with
HCV infection [35,48].
The increased frequency of the ATA haplotype in the control
group that was observed in our study was related to a lower riskof HCV infection and may be considered a protective factor in this
sample. The haplotypes GTA and ACC presented at a higher fre-
quency in HCV patients compared with healthy patients, as
reported in the study conducted by Afzal [22].
Regarding SVR, our data showed no signiﬁcant association with
the polymorphisms -1082 A/G, -819 C/T and -592 A/C, corroborat-
ing the study by Yee et al. [18,40,49]. However, an association
between polymorphisms of the IL-10 promoter and SVR was
observed, and the genotype -592 CC was more frequent in patients
who responded to antiviral therapy [48]. With regards to the SNP -
1082 AG, our results showed no signiﬁcant difference between the
groups of RVS and NR patients, as also observed by Pasha [44] and
Chuang [40]. However, these results contradict other studies that
demonstrated that the genotype -1082 GG was more common in
NR patients [39]. In fact, several studies have reported that geno-
types, haplotypes and serum levels of IL-10 have no signiﬁcant
effects on SVR and NR patients [40,43,50,51].
Considering the side effects and cost of antiviral therapy, the
determination of new genetic markers becomes crucial in thera-
peutic decisions prior to the onset of therapy in patients with
chronic hepatitis C. Our results contribute to the establishment
of possible genetic markers of response to the hepatitis C treat-
ment. This knowledge has a prognostic signiﬁcance in patients
chronically infected and may suggest a more aggressive therapy
for those with increased risk of disease progression. Our ﬁndings
about the HCV genotypes are notable. Although our results were
expected and similar ones have been extensively discussed in the
literature, they showed a smaller SVR in patients infected with
HCV genotype 1 and more advanced stages of ﬁbrosis in patients
infected with genotype 3 [52].
Because HCV infection involves numerous factors related to
both the host and the virus, the ambiguous and conﬂicting results
involving polymorphisms of IL-10, the progression of infection and
the response to antiviral therapy are within reason. It is important
to consider that the frequency of polymorphisms -1082 A/G, -819
C/T and -592 A/C was strongly related to ethnic and regional fac-
tors in the studied population. It has been shown that people of
European and Asian origin demonstrate drastically different pro-
duction levels of IL-10 [53]. Other studies have shown signiﬁcant
differences regarding the frequency of genotypes producing high
levels of IL-10 among black, Hispanic, Asian and Caucasian
individuals [54].
Despite the conﬂicting results found in our study, we showed an
association of the -1082 GG genotype with patients infected with
HCV and an association of the ATA haplotype with healthy individ-
uals. We hope that this study will contribute to the knowledge and
characterization of host restriction factors in HCV infection.Authors’ contributions
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